Chronic constipation affects approximately 14% of the adult population in the U.S. The most common types are chronic idiopathic constipation (CIC) and irritable bowel syndrome-associated constipation (IBS-C). Today, chronic constipation is treated with fiber, over-the-counter laxatives, and/or prescription drugs.
Current drugs for chronic constipation have very low response rates – under 20%. Because of these low response rates, chronic constipation patients often cycle through multiple medications without beneficial results. Approximately half of patients who initiate pharmacotherapy do not experience an adequate clinical response.
We recognize an urgent need for constipation therapy that’s more effective than current medications. We see an opportunity for consistently high response rates that can transform the lives of patients.
Anji Pharmaceuticals has a clinical trial for a new drug candidate for chronic constipation. Learn more and see if you’re eligible at the link below.